In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Kinetics’ Personal KinetiGraph Identifies Parkinson’s Patients Suitable For Deep Brain Stimulation

Executive Summary

A new study shows the Personal KinetiGraph wearable monitor can help clinicians identify the Parkinson’s disease patients most likely to benefit from device-assisted therapies, including deep brain stimulation.

You may also be interested in...



Global Kinetics Brings In Big Investments In Parkinson's Tracker

Global Kinetics has launched the global randomized Treat-to-Target trial of its Personal KinetiGraph Parkinson's disease monitor. This comes a few days after the publication of a a clinical trial showing how monitoring Parkinson's symptoms with the device can lead to improvements in patients' therapy.

Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry

The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.

Global Kinetics Kicks Off US Parkinson's Outcomes Trial For Wearable Monitor

The Australian company Global Kinetics has developed the Personal KinetiGraph, which includes a wearable smartwatch and a cloud-based system for continuous monitoring of Parkinson's disease symptoms to help improve patient management. KinetiGraph is 510(k)-cleared and CE marked, but the APPRISE multi-center trial will test the system’s ability to improve outcomes. The company hopes to convince US payers to cover it.

Topics

UsernamePublicRestriction

Register

MT125266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel